Fig. 2.

Overexpression of dPrp19 leads to dose-dependent extension of female but not male life span. Effects of the induction of the dPrp19 UAS cassette in three independent chromosomal insertions of the same transgenic construct on adult survival and dPrp19 mRNA levels: a, b TubGS-Gal4 > UAS-dPrp19-1 (females only), c–f daGS-Gal4 > UAS-dPrp19-2 (females and males), and g–j daGS-Gal4 > UAS-dPrp19-4 (females and males). a, c, e, g, and i show survival curves of experimental flies at three concentrations of the inducer drug RU486; b, d, f, h, and j show quantification of dPrp19 expression levels relative to the Rp49 control after 72 h of exposure to 300 µg/ml RU486. For all three overexpression constructs, we find a significant dose-dependent extension of female life span. Overall, we did not find any life span extension in males (for daGS-Gal4 > UAS-dPrp19-2 males at 100 µg/ml RU486 we observed a slight reduction in survival, possibly due to inadvertent ‘‘setup mortality” that might have occurred when the assay was set up). For details of life span statistics see Supplementary Table 1 (females) and Supplementary Table 2 (males); for experimental details see Materials and Methods